Published in J Med Chem on February 27, 2013
GPCR structure, function, drug discovery and crystallography: report from Academia-Industry International Conference (UK Royal Society) Chicheley Hall, 1-2 September 2014. Naunyn Schmiedebergs Arch Pharmacol (2015) 0.77
Targeting chemokine receptors in disease - a case study of CCR4. Eur J Pharmacol (2015) 0.75
Structure-activity relationship study and discovery of indazole 3-carboxamides as calcium-release activated calcium channel blockers. Bioorg Med Chem Lett (2016) 0.75
Discovery of AZD-2098 and AZD-1678, Two Potent and Bioavailable CCR4 Receptor Antagonists. ACS Med Chem Lett (2017) 0.75
Poxviruses and immune evasion. Annu Rev Immunol (2001) 4.80
A poxvirus-encoded pyrin domain protein interacts with ASC-1 to inhibit host inflammatory and apoptotic responses to infection. Immunity (2005) 3.43
Disruption of Erk-dependent type I interferon induction breaks the myxoma virus species barrier. Nat Immunol (2004) 2.51
Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. Proc Natl Acad Sci U S A (2006) 1.96
Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Mol Pharmacol (2003) 1.95
Four-pool modeling of proton exchange processes in biological systems in the presence of MRI-paramagnetic chemical exchange saturation transfer (PARACEST) agents. Magn Reson Med (2008) 1.85
Evaluation of Patient Navigation in a Community Radiation Oncology Center Involved in Disparities Studies: A Time-to-Completion-of-Treatment Study. J Oncol Pract (2008) 1.75
Role of the serine-threonine kinase PAK-1 in myxoma virus replication. J Virol (2003) 1.69
Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin. Cancer Res (2007) 1.50
RIG-I mediates the co-induction of tumor necrosis factor and type I interferon elicited by myxoma virus in primary human macrophages. PLoS Pathog (2008) 1.49
The right stuff for early intervention in psychosis: time, attitude, place, intensity, treatment, & cost. J Psychosoc Nurs Ment Health Serv (2005) 1.38
Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity. Drug Discov Today (2011) 1.36
Myxoma virus M11L prevents apoptosis through constitutive interaction with Bak. J Virol (2004) 1.27
Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells. J Virol (2006) 1.25
Ca2+ release-activated Ca2+ channel blockade as a potential tool in antipancreatitis therapy. Proc Natl Acad Sci U S A (2013) 1.23
A small zinc finger thylakoid protein plays a role in maintenance of photosystem II in Arabidopsis thaliana. Plant Cell (2011) 1.21
Myxoma virus M141R expresses a viral CD200 (vOX-2) that is responsible for down-regulation of macrophage and T-cell activation in vivo. J Virol (2005) 1.20
Neuronal eotaxin and the effects of CCR3 antagonist on airway hyperreactivity and M2 receptor dysfunction. J Clin Invest (2005) 1.20
Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo. Mol Ther (2007) 1.16
A Norway spruce FLOWERING LOCUS T homolog is implicated in control of growth rhythm in conifers. Plant Physiol (2007) 1.16
Pilot study: access to fitness facility and exercise levels in olanzapine-treated patients. Can J Psychiatry (2003) 1.14
Functional reconstitution of the mitochondrial Ca2+/H+ antiporter Letm1. J Gen Physiol (2013) 1.11
Oncolytic efficacy of recombinant vesicular stomatitis virus and myxoma virus in experimental models of rhabdoid tumors. Clin Cancer Res (2008) 1.08
Specific aspects of gastro-intestinal transit in children for drug delivery design. Int J Pharm (2010) 1.07
Dimeric zanamivir conjugates with various linking groups are potent, long-lasting inhibitors of influenza neuraminidase including H5N1 avian influenza. J Med Chem (2005) 1.07
Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach. J Med Chem (2010) 1.06
Myxoma virus M11L blocks apoptosis through inhibition of conformational activation of Bax at the mitochondria. J Virol (2006) 1.06
M-T5, the ankyrin repeat, host range protein of myxoma virus, activates Akt and can be functionally replaced by cellular PIKE-A. J Virol (2006) 1.05
Complete genomic sequence and comparative analysis of the tumorigenic poxvirus Yaba monkey tumor virus. J Virol (2003) 1.05
Definition of the heterocyclic pharmacophore of bacterial methionyl tRNA synthetase inhibitors: potent antibacterially active non-quinolone analogues. Bioorg Med Chem Lett (2004) 1.05
In vitro pharmacological characterization of vilanterol, a novel long-acting β2-adrenoceptor agonist with 24-hour duration of action. J Pharmacol Exp Ther (2012) 1.03
Metastatic susceptibility locus, an 8p hot-spot for tumour progression disrupted in colorectal liver metastases: 13 candidate genes examined at the DNA, mRNA and protein level. BMC Cancer (2008) 1.03
Arthroscopic assessment and classification of Kienbock's disease. Tech Hand Up Extrem Surg (2006) 1.02
A secreted high-affinity inhibitor of human TNF from Tanapox virus. Proc Natl Acad Sci U S A (2003) 1.02
Detection of circulating tumor cells in advanced head and neck cancer using the CellSearch system. Head Neck (2011) 1.02
The action of selective CRAC channel blockers is affected by the Orai pore geometry. Cell Calcium (2012) 1.02
Autophagy and metacaspase determine the mode of cell death in plants. J Cell Biol (2013) 0.99
A Pilot Study Comparing HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas by Whole Exome Sequencing. ISRN Oncol (2012) 0.97
CRACM/Orai ion channel expression and function in human lung mast cells. J Allergy Clin Immunol (2012) 0.96
Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases. J Pharmacol Exp Ther (2013) 0.95
High frequency of activating PIK3CA mutations in human papillomavirus-positive oropharyngeal cancer. JAMA Otolaryngol Head Neck Surg (2013) 0.95
Antitumor activity of ridaforolimus and potential cell-cycle determinants of sensitivity in sarcoma and endometrial cancer models. Mol Cancer Ther (2011) 0.94
Does HPV type affect outcome in oropharyngeal cancer? J Otolaryngol Head Neck Surg (2013) 0.94
Myxoma and vaccinia viruses exploit different mechanisms to enter and infect human cancer cells. Virology (2010) 0.93
Frequent mutations in TP53 and CDKN2A found by next-generation sequencing of head and neck cancer cell lines. Arch Otolaryngol Head Neck Surg (2012) 0.93
Characterization of selective Calcium-Release Activated Calcium channel blockers in mast cells and T-cells from human, rat, mouse and guinea-pig preparations. Eur J Pharmacol (2013) 0.92
Lignin biosynthesis in transgenic Norway spruce plants harboring an antisense construct for cinnamoyl CoA reductase (CCR). Transgenic Res (2007) 0.92
Poxvirus tumor necrosis factor receptor (TNFR)-like T2 proteins contain a conserved preligand assembly domain that inhibits cellular TNFR1-induced cell death. J Virol (2006) 0.89
Assessment of bitter taste of pharmaceuticals with multisensor system employing 3 way PLS regression. Anal Chim Acta (2013) 0.88
Induction of alpha/beta interferon by myxoma virus is selectively abrogated when primary mouse embryo fibroblasts become immortalized. J Virol (2009) 0.88
Spruce embryogenesis. Methods Mol Biol (2008) 0.87
Early cone setting in Picea abies acrocona is associated with increased transcriptional activity of a MADS box transcription factor. Plant Physiol (2012) 0.86
Comparative genetic analysis of genomic DNA sequences of two human isolates of Tanapox virus. Virus Res (2007) 0.86
4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists. J Med Chem (2007) 0.85
Myxoma virus selectively disrupts type I interferon signaling in primary human fibroblasts by blocking the activation of the Janus kinase Tyk2. Virology (2009) 0.85
Electronic tongue for pharmaceutical analytics: quantification of tastes and masking effects. Anal Bioanal Chem (2004) 0.84
Analysis of essential Arabidopsis nuclear genes encoding plastid-targeted proteins. PLoS One (2013) 0.84
Tropism of Tanapox virus infection in primary human cells. Virology (2007) 0.83
Distinct conformations of the chemokine receptor CCR4 with implications for its targeting in allergy. J Immunol (2014) 0.83
Solid-state NMR analysis of a boron-containing pharmaceutical hydrochloride salt. J Pharm Sci (2013) 0.82
Performance of a redesigned HIV Selectest enzyme-linked immunosorbent assay optimized to minimize vaccine-induced seropositivity in HIV vaccine trial participants. Clin Vaccine Immunol (2014) 0.82
Lead optimisation of the N1 substituent of a novel series of indazole arylsulfonamides as CCR4 antagonists and identification of a candidate for clinical investigation. Bioorg Med Chem Lett (2012) 0.82
High glucose and diabetes enhanced store-operated Ca(2+) entry and increased expression of its signaling proteins in mesangial cells. Am J Physiol Renal Physiol (2014) 0.82
Viral retasking of hBre1/RNF20 to recruit hPaf1 for transcriptional activation. PLoS Pathog (2013) 0.81
CRAC channel inhibition produces greater anti-inflammatory effects than glucocorticoids in CD8 cells from COPD patients. Clin Sci (Lond) (2014) 0.81
A study of hydrogen peroxide chemistry and photochemistry in tea stain solution with relevance to clinical tooth whitening. J Dent (2012) 0.81
Ki-67 expression predicts radiotherapy failure in early glottic cancer. J Otolaryngol Head Neck Surg (2012) 0.81
Potent oncolytic activity of raccoonpox virus in the absence of natural pathogenicity. Mol Ther (2010) 0.81
A specific CCR3 chemokine receptor antagonist inhibits both early and late phase allergic inflammation in the conjunctiva. Immunol Res (2005) 0.81
Elucidating the pathways of degradation of denagliptin. J Pharm Sci (2010) 0.81
Dendritic cell internalization of foam-structured fluorescent mesoporous silica nanoparticles. J Colloid Interface Sci (2010) 0.80
The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis. J Med Chem (2011) 0.80
Myxoma virus expressing human interleukin-12 does not induce myxomatosis in European rabbits. J Virol (2007) 0.80
Variation in ligand binding specificities of a novel class of poxvirus-encoded tumor necrosis factor-binding protein. J Biol Chem (2006) 0.80
Raccoonpox in a Canadian cat. Vet Dermatol (2006) 0.80
Oxazolidinones as novel human CCR8 antagonists. Bioorg Med Chem Lett (2006) 0.80
4-Phenyl-7-azaindoles as potent, selective and bioavailable IKK2 inhibitors demonstrating good in vivo efficacy. Bioorg Med Chem Lett (2012) 0.80
Exploiting high-throughput cell line drug screening studies to identify candidate therapeutic agents in head and neck cancer. BMC Pharmacol Toxicol (2014) 0.79
Psychotic disorders clinic and first-episode psychosis: a program evaluation. Can J Psychiatry (2005) 0.79
Yaba monkey tumor virus encodes a functional inhibitor of interleukin-18. J Virol (2007) 0.79
No time for spruce: rapid dampening of circadian rhythms in Picea abies (L. Karst). Plant Cell Physiol (2013) 0.79
Asymmetric synthesis of an N-acylpyrrolidine for inhibition of HCV polymerase. J Org Chem (2008) 0.79
4-Phenyl-7-azaindoles as potent and selective IKK2 inhibitors. Bioorg Med Chem Lett (2009) 0.79
A promoter from the loblolly pine PtNIP1;1 gene directs expression in an early-embryogenesis and suspensor-specific fashion. Planta (2002) 0.79